비씨월드제약

200780KOSDAQ의약품 제조업

45.3 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Plunged 18.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BC World Pharm focuses on R&D of new and improved drugs, maintaining competitiveness in both domestic and international markets by exporting specialty pharmaceuticals produced in facilities compliant with FDA and EMA standards. The company is expanding its CMO/CDMO business and pursuing overseas licensing deals, addressing growing pharmaceutical demand driven by aging populations.

Number of Employees

288people

Average Salary

40.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

0.53Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

-4.23Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

20.12Industry Average 12.430.5Point

1.6x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼21.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
비씨월드제약 "P-CAB계열 위장질환 치료제 허가"
비씨월드제약의 P-CAB 계열 위장질환 치료제 '보신티' 제네릭 허가로 상용화 기대감 증가.
Positive
비씨월드제약, 1분기 연결 영업이익 18억
비씨월드제약의 1분기 실적이 흑자 전환하며 매출이 전년 대비 25% 성장, 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 3,635Won52-week high 5,87052-week low 3,610

1-month return0.0Point

1m -18.04% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-13